Pre-market · Regular session opens 9:30 AM ET
Last update: Oct 30, 2026, 6:17 PM ET

Stock Analysis

IonQ (IONQ) Falls ~9% on a $1.3B All-Stock Cybersecurity Acquisition

IonQ fell about 9% to roughly $36 on October 12 on a day it announced a definitive agreement to acquire Elisity, a zero-trust cybersecurity company, in an all-stock deal worth up to $1.3 billion. The counterintuitive part is the point: a stock dropping on its own acquisition. The all-stock structure is why — IonQ's share count is already up about 50% over the past year as it funds an acquisition-and-fundraising spree largely with stock, and Elisity is its third billion-dollar-scale deal in roughly 16 months, after the mostly-stock Oxford Ionics purchase and the cash-and-stock SkyWater acquisition. The strategic logic is forward-looking (pairing post-quantum cryptography with Elisity's zero-trust platform to sell 'quantum-era' security), but the market read the news as more dilution and more strategic sprawl from a pre-profit company valued near $14 billion on just $246 million of revenue — about 58 times sales, with an operating margin near negative 380%. A sign of company-specific pressure: IonQ fell about 9% while quantum peers Rigetti and D-Wave fell closer to 5.5% and the Nasdaq-100 slipped under 1% — more than the sector alone would explain. Wall Street stays overwhelmingly bullish on the long-term quantum roadmap — a Strong Buy consensus with an average target far above the price — which is exactly why a story stock like this swings so violently on news.

By Roberto LiccardoPublished (ET)10 min readIONQ
An abstract visualization of a falling stock chart over a quantum-circuit and network-security motif in cool violet and red tones, representing IonQ's drop on its all-stock Elisity cybersecurity acquisition.

Why IonQ stock fell — a $1.3 billion acquisition the market didn't love

On Monday, October 12, 2026, IonQ (NYSE: IONQ) fell about 9%, trading near $36.24 intraday, on a day the company announced a definitive agreement to acquire Elisity, a zero-trust cybersecurity company, in an all-stock deal worth up to $1.3 billion [2]. The counterintuitive part is the one that matters: a stock falling on its own acquisition news. The move was a mix of two things — a broad sell-off in speculative quantum-computing names, and a company-specific verdict on the deal itself, which IonQ underperformed its quantum peers by several points to deliver [1][5]. In plain terms, the market read the deal as more dilution and more sprawl, not more value — at least on day one.

The all-stock structure is central to the reaction. IonQ will pay in shares, not cash, with the final count set at closing from a 20-day average price and collared between roughly $33 and $50 a share [2]. Because IonQ's share count has already risen about 50% over the past year as it funds an acquisition-and-fundraising spree largely with stock, another all-stock deal lands on shareholders who are already being diluted [3]. And this is not a one-off: Elisity is IonQ's third billion-dollar-scale acquisition in roughly 16 months, following the roughly $1.07 billion, mostly-stock purchase of Oxford Ionics (completed in 2025) and the roughly $1.8 billion cash-and-stock acquisition of chipmaker SkyWater Technology (completed in 2026) [2].

The deal — and the strategic pivot it represents

Elisity sells software that stops attackers and ransomware from moving laterally through corporate networks; it says it has more than 100 deployments, counts hospitals and healthcare companies among its customers, and reports no churn among deployed customers, though IonQ disclosed no revenue figure [2]. Its product addresses present-day enterprise security; the quantum angle is prospective. The strategic logic IonQ offered is forward-looking: pairing its post-quantum cryptography and quantum key distribution work with Elisity's zero-trust platform to sell "quantum-era" security — the idea being that powerful quantum computers will eventually break today's encryption, so protecting networks against that future is a potential growth market. Chief executive Niccolo de Masi framed it as positioning IonQ to "help customers protect critical infrastructure and enterprise networks throughout the transition to the quantum era" [2]. The headline figure includes up to $150 million of performance-based earnouts, so the amount paid at closing — expected in the fourth quarter, subject to regulators — will be below the $1.3 billion ceiling [2].

Two-panel chart titled 'IonQ (IONQ): sold off on its own acquisition, more than its quantum peers.' The left panel shows October 12 intraday moves: IonQ down about 9.2%, Rigetti down about 5.5%, D-Wave down about 5.6%, and the Nasdaq-100 ETF QQQ down about 0.8%. The right panel shows context: IonQ's roughly $14.4 billion market value against just $246 million of trailing revenue (a price-to-sales ratio near 58), an operating margin around minus 382 percent, a share count up about 50 percent over the past year, and the up-to-$1.3 billion all-stock Elisity deal. A stat strip shows the roughly 9% drop, the price-to-sales ratio near 58, the $2.06 billion net-cash balance, and that this is IonQ's third billion-dollar-scale acquisition in roughly 16 months.
IonQ fell about 9% on its own up-to-$1.3 billion, all-stock acquisition of Elisity — underperforming quantum peers Rigetti and D-Wave (both down about 5.5%) on a down day for the group, while the Nasdaq-100 slipped less than 1%. The larger drop points to company-specific pressure — dilution and strategic-fit concerns — on top of the sector move (intraday readings, ~2:22 p.m. ET, October 12, 2026). Sources: StockAnalysis; company release via press reports; market data, Oct 2026.

The reasons for skepticism

The sell-off is easier to understand once the valuation is in view. IonQ is a pre-profit quantum-computing company carrying a market value near $14 billion on roughly $246 million of trailing revenue — a price-to-sales ratio around 58 — with an operating margin of about negative 380% and no earnings [3]. Much of its reported revenue growth is itself acquisition-fueled. A company valued almost entirely on a long-dated story is especially sensitive to anything that adds shares or muddies the narrative, and an all-stock purchase of a cybersecurity firm does both. There is also a strategic-coherence question: IonQ builds quantum-computing hardware, and buying a network-security software vendor is a meaningful pivot whose synergies are conceptual rather than proven. As a rough illustration (before any contingent earnout shares, and sensitive to the closing price within the collar), the Elisity deal alone could issue new shares worth something like 6% to 8% of the enlarged company. Notably, IonQ holds about $2.06 billion of net cash, so it could have paid cash — choosing stock preserves that buffer for a business that burns heavily (and is already funding its other acquisitions, losses and research), but it puts the cost of the deal on existing shareholders [3]. A sign that the deal, not just the sector, weighed on the stock: IonQ fell about 9% while fellow quantum names Rigetti and D-Wave fell closer to 5.5% and the Nasdaq-100 dropped under 1% — suggesting company-specific pressure on top of a broad quantum sell-off [5].

Why it matters

IonQ has become a bellwether for the quantum-computing trade — a small-revenue company with a large valuation, using its richly priced stock as currency to buy its way toward scale and adjacency. Monday's reaction is a useful check on that model: the market will applaud ambition only up to the point where the dilution bill comes due, and a large all-stock deal layered onto an aggressive expansion appears to have reached it. The cross-section underscores that the move was partly sector and partly specific. Quantum peers fell together in a risk-off session for speculative, high-multiple technology, but IonQ fell roughly a third more than they did — pointing to company-specific pressure from the deal on top of the sector move, rather than that gap being a precise measure of it [5]. The episode is also a reminder of how two-sided these names are: the same stock that analysts peg far above its current price can drop 9% in an afternoon on a strategic announcement, because so much of the value rests on a future that has not yet arrived — and on a share count that keeps growing.

The move, in one cross-section

The same-session tape shows a sector sell-off with a company-specific overshoot [5]:

Name (ticker)Oct 12, 2026 (intraday)Read-through
IONQ — IonQ≈−9.2%The acquirer — down on dilution and strategic-fit concerns over the Elisity deal [1][2]
RGTI — Rigetti Computing≈−5.5%Quantum peer — down on a sector risk-off, with no deal of its own [5]
QBTS — D-Wave Quantum≈−5.6%Quantum peer — down with the group [5]
QQQ — Nasdaq-100 (ETF)≈−0.8%Broad tech — modestly lower; the quantum names fell far more [5]

Quantum peers down about 5.5% point to a sector move; IonQ down about 9% points to that plus company-specific pressure — the signature of a stock selling off on its own news [5].

What the Street thinks

Wall Street's posted view is strikingly bullish relative to the tape. The consensus rating is a Strong Buy, with an average 12-month target near $67 — well above the roughly $36 where the stock traded on Monday — within a very wide range from about $42 to $100 [6]. That dispersion is the story: analysts are underwriting IonQ's long-term quantum roadmap, not the economics of a cybersecurity acquisition, and the targets should be read as bets on the platform rather than endorsements of this deal — and the posted consensus may not yet reflect the Elisity transaction at all. It is worth holding that optimism against the fundamentals — no profits, heavy cash burn, a price-to-sales multiple near 58, and a share count rising about 50% a year — which is precisely the gap that makes a name like this swing violently on news. The bullish consensus and the 9% drop are not contradictory; they are the two halves of a story stock.

What to watch

  • Dilution and the share count. How many shares the all-stock deal ultimately issues within its roughly $33–$50 collar, on top of a count already up about 50% over the past year [2].
  • Deal close and regulatory review. Whether the Elisity acquisition closes in the fourth quarter as planned, and on what final terms [2].
  • November 4 earnings. The next hard read on revenue, cash burn, and how the SkyWater, Oxford Ionics and Elisity acquisitions are being integrated [3].
  • Quantum-sector sentiment. Whether the high-beta quantum group stabilizes or keeps de-rating, which will move IonQ regardless of the deal. Moves are tracked on the IONQ stock page [5].

Illustrative scenario sensitivity

Because IonQ is a pre-profit, narrative-driven stock, the scenarios below are anchored to the deal, dilution, and quantum-sector sentiment rather than to earnings or a single valuation — this is an unusually speculative, high-volatility name, and the dispersion is wide [6]. They are a descriptive, author-weighted exercise over roughly the coming six-to-twelve months as the deal closes and sentiment shifts — not a forecast, target, recommendation, or trading advice — with subjective weights that sum to 100%.

ScenarioIllustrative priceWeightKey drivers
Quantum narrative reaccelerates~$5225%Dilution fears fade, the "quantum-era security" story gains traction, and high-beta quantum momentum resumes, re-rating the stock back toward analyst targets [6].
Range-bound and volatile~$3735%The deal closes and IonQ keeps executing, but added shares offset growth and the stock stays choppy near current levels [3].
Dilution fatigue / sector de-rating~$2740%Serial stock-funded M&A and a broader quantum pullback weigh on a high-beta, pre-profit name, pulling it toward the low end of its 52-week range [1].

Weighting those (0.25 × $52 + 0.35 × $37 + 0.40 × $27) gives an author-weighted reference value near $37 — an illustrative, probability-weighted scenario output mechanically derived from the weights above, and not a price target, fair-value estimate, or prediction — essentially level with Monday's ~$36 intraday price [1][6]. The near-identity reflects a balanced but extraordinarily wide-dispersion setup: a stock where a credible long-term story and a real near-term dilution problem roughly offset, and where the outcome hinges far more on quantum-sector sentiment than on this one deal. This is a scenario exercise and descriptive analysis of a news-driven move, not investment advice.

IONQ data snapshot — October 12, 2026

FigureValueAs-of / source
Intraday quote~$36.24 (−~9.2%) — an intraday reading (the session was open)Mon, Oct 12, 2026, ~2:22pm ET — StockAnalysis [1]
Prior close / open / range$39.89 prior close; opened $38.79; day range $35.89–$38.81Oct 12, 2026 [1]
TradingAn active session on a news catalyst; beta ≈3.36 (very high) amplifies sector movesOct 12 — StockAnalysis [1]
52-week trend52-week range $25.89–$84.64; down ~49% over 52 weeks, well off the high and below the 50-day average (~$41)As of Oct 12 [3]
Market cap≈$14.40B (≈397.3M shares); enterprise value ≈$12.38BOct 12 — StockAnalysis [3]
ValuationPre-profit: no P/E (EPS ≈−$3.99); price-to-sales ≈58× (forward ≈21×); gross margin ≈31%, operating margin ≈−382%Oct 12 — StockAnalysis [3]
Financials (TTM)Revenue ≈$246M (+~371%, largely acquisition-fueled); net loss; net cash ≈$2.06B (cash ≈$2.12B, debt ≈$55M); shares up ~50% YoYTTM — StockAnalysis [3]
CatalystIonQ announced a definitive agreement to acquire Elisity (zero-trust cybersecurity) in an all-stock deal worth up to $1.3B (incl. up to $150M earnout; share consideration collared ~$33–$50; closing Q4 2026). Rationale: "quantum-era" security. The stock fell ~9%, which market reporting tied to dilution and strategic-fit concerns — IonQ's third billion-dollar-scale acquisition in ~16 months (after Oxford Ionics, mostly stock, and SkyWater, cash-and-stock)Oct 12, 2026 — company release via press reports [2]
Same-day cross-sectionRGTI −5.5%, QBTS −5.6% (quantum peers); QQQ −0.8% (Nasdaq-100) — IonQ underperformed the group by ~3.6ppOct 12 intraday [5]
Analyst viewConsensus Strong Buy, avg target ~$66.63 (low $41.85, high $100) — well above the price; next earnings Nov 4, 2026Oct 12, 2026 — StockAnalysis / analyst notes [6]

IonQ (IONQ) stock FAQ

Why did IonQ (IONQ) stock fall on October 12, 2026?

IonQ fell about 9% to roughly $36 on the same day it announced a definitive agreement to acquire Elisity, a zero-trust cybersecurity company, in an all-stock deal worth up to $1.3 billion. A stock falling on its own acquisition is counterintuitive, but the reaction reflects two things. First, the all-stock structure adds dilution: IonQ's share count is already up about 50% over the past year as it funds an acquisition-and-fundraising spree largely with stock, and this is its third billion-dollar-scale deal in roughly 16 months. Second, it raises a strategic-fit question — a quantum-computing hardware company buying a network-security software firm is a notable pivot. The quantum sector was also broadly lower that day, but IonQ fell roughly a third more than peers Rigetti and D-Wave, suggesting company-specific pressure on top of the sector selloff.

What is IonQ buying, and why?

IonQ agreed to acquire Elisity, which makes software that prevents attackers and ransomware from spreading laterally through corporate networks. Elisity says it has more than 100 deployments and counts hospitals and healthcare companies among its customers, though IonQ disclosed no revenue figure. The strategic rationale is forward-looking: IonQ wants to combine its post-quantum cryptography and quantum key distribution work with Elisity's zero-trust platform to sell 'quantum-era' cybersecurity. The premise is that powerful quantum computers will eventually be able to break today's encryption, so defending networks against that future is a potential growth market. CEO Niccolo de Masi framed the deal as positioning IonQ to protect critical infrastructure through the transition to the quantum era. The deal is worth up to $1.3 billion, including up to $150 million in performance-based earnouts, and is expected to close in the fourth quarter of 2026.

Why is dilution such a concern for IonQ shareholders?

Because IonQ pays for acquisitions with its own stock rather than cash, every deal issues new shares and dilutes existing holders. Its share count is already up about 50% over the past year (from stock-funded deals and capital raises), and Elisity is its third billion-dollar-scale acquisition in roughly 16 months — after the roughly $1.07 billion, mostly-stock purchase of Oxford Ionics (completed in 2025) and the roughly $1.8 billion cash-and-stock acquisition of chipmaker SkyWater Technology (completed in 2026). The Elisity deal is all-stock, with the final share count set at closing from a 20-day average price, collared between about $33 and $50 — a mechanical illustration suggests it would issue new shares worth roughly 6% to 8% of the enlarged company. Notably, IonQ holds about $2.06 billion of net cash and could have paid cash; choosing stock preserves that cash for a business that burns heavily, but it puts the cost of the deal on shareholders. For a pre-profit company valued largely on a long-term story, serial stock-funded M&A is a meaningful headwind.

Is IonQ profitable, and how is it valued?

No, IonQ is not profitable — it reported a net loss, has no price-to-earnings ratio, and runs an operating margin around negative 380%, meaning it spends far more than it earns. It is valued as a long-term story stock: a market capitalization near $14 billion against only about $246 million of trailing revenue, which is a price-to-sales ratio near 58 (its reported revenue growth is also heavily acquisition-fueled). The company does carry a strong balance sheet, with about $2.06 billion of net cash, and its revenue is growing quickly. But a valuation resting almost entirely on the future of quantum computing is highly sensitive to anything that adds shares or complicates the narrative — which is why the stock is unusually volatile, carries a very high beta, and is down about 49% over the past 52 weeks even after a strong prior run.

What do analysts think about IonQ stock?

Wall Street's posted view is strikingly bullish relative to the stock's recent action. The consensus rating is a Strong Buy, with an average 12-month price target near $67 — well above the roughly $36 where the stock traded on October 12 — within a very wide range from about $42 to $100. That dispersion is the key point: analysts are underwriting IonQ's long-term quantum-computing roadmap, not the economics of a cybersecurity acquisition, so the targets are better read as bets on the platform than as endorsements of this particular deal. The optimism should be weighed against the fundamentals — no profits, heavy cash burn, a price-to-sales multiple near 58, and a share count rising about 50% a year — which is exactly the gap that makes the stock swing sharply on news. A bullish consensus and a 9% single-day drop are the two halves of a story stock.

What should investors watch next for IonQ?

Four things. First, dilution: how many shares the all-stock Elisity deal ultimately issues within its roughly $33–$50 collar, on top of a share count already up about 50% over the past year. Second, the deal's progress — whether it closes in the fourth quarter of 2026 as planned and clears regulatory review. Third, IonQ's own earnings on November 4, 2026, the next hard read on revenue, cash burn, and how its recent acquisitions (Oxford Ionics, SkyWater and Elisity) are being integrated. Fourth, quantum-sector sentiment: IonQ is a high-beta name that moves with the broader quantum-computing trade regardless of its own news, so the group's direction matters as much as the deal. Because so much of the value rests on a long-dated story, the stock is likely to stay headline-sensitive and volatile.

View all research →
An abstract visualization of a falling stock chart over a search and AI motif in orange-red tones, representing Reddit's crash after a Q3 revenue beat was overshadowed by a Google AI search-traffic warning.
Stock AnalysisOctober 30, 2026 · 12 min read

Reddit (RDDT) Crashes ~30% After a Q3 Beat on a Google AI Search-Traffic Warning

Reddit crashed about 30% to roughly $90.79 on October 30 — a striking reaction, because the quarter itself was strong: revenue of $895 million rose 53% year over year, a clear beat, with net income of $283 million, diluted EPS of $1.40 and adjusted EBITDA of $402 million. The stock cratered on what management said about the future. On the earnings call, CEO Steve Huffman warned that search referrals fell more than a million per week on average in October as Google answers more queries with AI, and that daily active users (around 130 million) could fall a low-double-digit percentage in the fourth quarter if the trend held. Investors also fixed on a 2% year-over-year decline in US daily actives — Reddit's most valuable market, where revenue per user is more than five times the international level — and on fourth-quarter revenue guidance of $1.00–$1.03 billion that came in below expectations; Citizens downgraded the stock before the open. The one bullish counterweight was monetization: revenue per user still jumped 36% globally. The move was company-specific — Reddit's roughly 30% drop was about four times the moves of social peers Snap and Pinterest (each down ~7%), on a day the broad market fell about 2%. After the crash Reddit trades at roughly 14 times forward earnings with about $3 billion of net cash — not expensive for 50%-plus growth, if the growth is durable. The whole debate is whether rising revenue per user can keep outrunning a top of the funnel that AI search is draining.

An abstract visualization of a falling stock chart over an automotive and circuit-grille motif in steel-blue and red tones, representing General Motors' drop after a Q3 beat-and-raise was overshadowed by 2027 cost and EV concerns.
Stock AnalysisOctober 20, 2026 · 10 min read

General Motors (GM) Falls ~8% Despite a Q3 Beat and a $20B Buyback

General Motors fell about 8% to roughly $75.77 on October 20 — a striking reaction, because GM beat on third-quarter earnings, raised its full-year profit outlook and announced a $20 billion buyback. Adjusted earnings of $3.70 a share topped estimates on revenue of about $50 billion, and GM lifted the midpoint of its full-year adjusted-EPS guidance to about $13.25 (from $13.00) and raised its free-cash-flow outlook. The stock fell anyway on what the guidance implied, not the quarter. The full-year outlook implies a softer fourth quarter — only about $2.7 billion of operating profit versus $4.1 billion in the third, as a Silverado/Sierra redesign temporarily cuts truck deliveries by roughly 35,000 units — the raised $13.25 EPS midpoint still landed just below the roughly $13.41 the Street expected, and management flagged about $2 billion of 2026 cost inflation plus a conditional scenario of more in 2027. Two things that look like culprits mostly were not: the 62% drop in EV sales was already known and reflects a distorted 2025 comparison, and tariff costs are now expected near the low end of an existing range. Crucially, GM did not cut its 2027 outlook — it still expects next year to improve if conditions hold. The move was clearly company-specific — Ford fell only about 1%, Stellantis was flat and the S&P 500 rose — so this was a repricing of GM's forward earnings, not an auto-sector sell-off. The valuation captures the tension: GM trades at barely five to six times the forward earnings it guides to, extraordinarily cheap, because the market prices automakers for the downturn, not the peak. A $20 billion buyback into that multiple is powerfully accretive if earnings hold — but whether they hold in 2027 is exactly the question. Analysts keep a Buy consensus and an average target near $104.

An abstract visualization of a rising stock chart over a molecular antibody and DNA-helix motif in cool teal and violet tones, representing Summit Therapeutics' jump on a new ivonescimab kidney-cancer trial.
Stock AnalysisOctober 19, 2026 · 10 min read

Summit Therapeutics (SMMT) Jumps ~6% on a New Ivonescimab Kidney-Cancer Trial

Summit Therapeutics rose about 6% to roughly $15.57 on October 19 after announcing it had opened a global Phase II trial of ivonescimab — its closely watched lead drug — in previously untreated advanced clear cell kidney cancer, with partner Akeso. The key nuance: this is the opening of a mid-stage study, not a data readout, so it is an incremental catalyst that expands the story rather than one that proves it. Summit is effectively a one-drug company: ivonescimab is a PD-1/VEGF bispecific antibody, licensed from China's Akeso, that outperformed Merck's Keytruda in a Chinese lung-cancer trial — nearly doubling progression-free survival and, in updated data, delivering a significant overall-survival benefit (30.8 vs 22.6 months) — though the global trial behind its U.S. filing has yet to formally confirm that survival benefit in Western patients. With no product revenue and a market value above $12 billion, essentially all of Summit's worth is the market's bet on that drug, so a new indication is a fresh call option on the thesis. Two bigger items frame it: AstraZeneca agreed in late September to invest about $2 billion in Summit equity (a ~12% stake), transforming the balance sheet and removing the financing overhang, and the FDA has a November 14, 2026 decision date on ivonescimab in EGFR-mutated lung cancer — a near-term, binary catalyst that matters far more than a trial start. Monday's move was partly company-specific and partly a tailwind: biotech broadly rallied, with the sector ETF up about 2.5%, but Summit outperformed. The risks are a binary valuation on one molecule, an unconfirmed Western survival benefit, and a stock down roughly 47% from its high. Analysts carry a Buy consensus and an average target near $30, inside a wide range from about $12 to the mid-$40s.